Usefulness of Self-Expandable Stent for Recanalization of Intracranial Atherosclerotic Disease: Preliminary Experience with Enterprise Stent.

IF 1.2 Q4 CLINICAL NEUROLOGY
Neurointervention Pub Date : 2022-03-01 Epub Date: 2022-02-21 DOI:10.5469/neuroint.2022.00017
Woo Sang Jung, Sam-Soo Kim, Kyung-Yul Lee, Sang Hyun Suh
{"title":"Usefulness of Self-Expandable Stent for Recanalization of Intracranial Atherosclerotic Disease: Preliminary Experience with Enterprise Stent.","authors":"Woo Sang Jung,&nbsp;Sam-Soo Kim,&nbsp;Kyung-Yul Lee,&nbsp;Sang Hyun Suh","doi":"10.5469/neuroint.2022.00017","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this preliminary study is to evaluate the efficacy and safety of the Enterprise stent for intracranial atherosclerotic disease (ICAD) in patients who presented with acute stroke due to vessel steno-occlusion and in patients with symptomatic disease despite optimum medical management.</p><p><strong>Materials and methods: </strong>A retrospective data analysis was performed on 15 consecutive patients who were treated with Enterprise stenting for recanalization of symptomatic intracranial steno-occlusive arteries due to underlying ICAD. Their clinical and radiological data were reviewed to evaluate procedural results, periprocedural and postprocedural complications, and clinical outcome.</p><p><strong>Results: </strong>Enterprise stents were deployed as a rescue method in 15 patients for recanalization of steno-occlusion. All patients achieved final modified thrombolysis in cerebral infarction (mTICI) score improvement (53.3% with a mTICI score from 0 to 2b or 3, 46.7% with a mTICI score from 1 to 3). Two postprocedural complications (1 symptomatic intracranial hemorrhage and 1 severe brain edema, 13.3%) occurred among 15 patients. Among 12 patients with acute ischemic stroke (AIS), 6 patients (50%) had improvement in their National Institute of Health Stroke Scale of more than 4 at discharge. Seven patients (58.3%) had a good functional outcome with 3-month modified Rankin Score (mRS)≤2, and mortality occurred (mRS=6) in 2 patients (16.7%). None of the 10 AIS and 3 transient ischemic attack patients experienced further ischemic events attributable to the treated steno-occlusion during the follow-up period (ranged from 4 to 36 months, median 12 months).</p><p><strong>Conclusion: </strong>This retrospective study suggests that Enterprise stenting can effectively and safely achieve recanalization in symptomatic steno-occlusive intracranial arteries.</p>","PeriodicalId":19140,"journal":{"name":"Neurointervention","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/6f/neuroint-2022-00017.PMC8891589.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurointervention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5469/neuroint.2022.00017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Purpose: The purpose of this preliminary study is to evaluate the efficacy and safety of the Enterprise stent for intracranial atherosclerotic disease (ICAD) in patients who presented with acute stroke due to vessel steno-occlusion and in patients with symptomatic disease despite optimum medical management.

Materials and methods: A retrospective data analysis was performed on 15 consecutive patients who were treated with Enterprise stenting for recanalization of symptomatic intracranial steno-occlusive arteries due to underlying ICAD. Their clinical and radiological data were reviewed to evaluate procedural results, periprocedural and postprocedural complications, and clinical outcome.

Results: Enterprise stents were deployed as a rescue method in 15 patients for recanalization of steno-occlusion. All patients achieved final modified thrombolysis in cerebral infarction (mTICI) score improvement (53.3% with a mTICI score from 0 to 2b or 3, 46.7% with a mTICI score from 1 to 3). Two postprocedural complications (1 symptomatic intracranial hemorrhage and 1 severe brain edema, 13.3%) occurred among 15 patients. Among 12 patients with acute ischemic stroke (AIS), 6 patients (50%) had improvement in their National Institute of Health Stroke Scale of more than 4 at discharge. Seven patients (58.3%) had a good functional outcome with 3-month modified Rankin Score (mRS)≤2, and mortality occurred (mRS=6) in 2 patients (16.7%). None of the 10 AIS and 3 transient ischemic attack patients experienced further ischemic events attributable to the treated steno-occlusion during the follow-up period (ranged from 4 to 36 months, median 12 months).

Conclusion: This retrospective study suggests that Enterprise stenting can effectively and safely achieve recanalization in symptomatic steno-occlusive intracranial arteries.

Abstract Image

Abstract Image

自膨胀支架在颅内动脉粥样硬化疾病再通中的应用:企业支架的初步经验。
目的:本初步研究的目的是评估Enterprise支架治疗颅内动脉粥样硬化性疾病(ICAD)的有效性和安全性,这些患者因血管狭窄闭塞而出现急性卒中,尽管有最佳的医疗管理,但仍有症状。材料和方法:回顾性分析15例连续行Enterprise支架治疗因ICAD所致症状性颅内狭窄闭塞动脉再通的患者。我们回顾了他们的临床和放射学资料,以评估手术结果、手术期间和术后并发症以及临床结果。结果:15例狭窄闭塞再通患者采用企业支架进行抢救。所有患者最终改良溶栓脑梗死(mTICI)评分改善(53.3%,mTICI评分为0 ~ 2b, 46.7%, mTICI评分为1 ~ 3)。15例患者发生2例术后并发症(1例症状性颅内出血,1例重度脑水肿,13.3%)。12例急性缺血性脑卒中(AIS)患者中,6例(50%)患者出院时国立卫生研究院卒中量表改善4分以上。7例(58.3%)功能预后良好,3个月改良Rankin评分(mRS)≤2,2例(16.7%)出现死亡(mRS=6)。随访期间(4 ~ 36个月,中位12个月),10例AIS患者和3例短暂性脑缺血发作患者均未因治疗后的狭窄闭塞发生进一步的脑缺血事件。结论:本回顾性研究表明,对于有症状的颅内动脉狭窄闭塞,企业支架置入术可以有效、安全地实现再通。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
34
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信